Poor
Not Aligned
Patient Risk:
Moderate
Summary
Several claims are not supported by the supplied label excerpts (e.g., long-term use duration, diabetes risk magnitude, cognitive effects, sodium diet effects, electrolyte monitoring, CK/HbA1c monitoring schedules, interaction with low-sodium diets, specific adverse-event incidence ranges). Some claims are directionally supported (e.g., muscle pain/myopathy and liver enzyme abnormalities, pregnancy and breastfeeding contraindications, key interaction with cyclosporine), but multiple material mismatches reduce overall alignment.
Category Scores
Accurate Statements
Pregnancy prohibits use of Lipitor.
Label contraindicates women who are pregnant or may become pregnant (Section 4; Section 8.1 Pregnancy Category X).
Breastfeeding prohibits use of Lipitor.
Label advises women requiring LIPITOR treatment should not nurse infants (Section 4 and Section 8.3 Nursing Mothers).
Active liver disease is a reason to avoid or use caution with Lipitor.
Active liver disease is a contraindication (Section 4); active liver disease or unexplained persistent transaminase elevations are contraindications (Section 5.2).
Unexplained muscle pain is a reason to avoid or use caution with Lipitor.
Label advises reporting unexplained muscle pain (Section 17.1) and notes therapy should be withheld/discontinued with an acute, serious condition suggestive of myopathy (Section 5.1).
Cyclosporine is an interacting drug where caution/avoidance is recommended with Lipitor.
Label states in cases of co-administration, dose should not exceed 10 mg (Section 7.3).
Muscle pain (myalgia) affects 5–10% of users of Lipitor.
Not supported as stated; however label does document myalgia as a common adverse reaction leading to discontinuation (Section 6.1). Label excerpt provides 0.7% discontinuation rate, not incidence range.
Unsupported Statements
Lipitor (atorvastatin) is FDA-approved for long-term use in adults.
Supplied label excerpts do not state an approval for 'long-term use' duration in adults.
Lipitor is used in adults to lower cholesterol.
While lipid-lowering purpose is implied by Sections 1 and 14.2 excerpts, the claim is not explicitly stated for 'adults' in the provided indication excerpts.
Lipitor reduces cardiovascular risk.
The label excerpt includes relative risk reductions for coronary/major cardiovascular events (Section 14), but the provided excerpts are not sufficient to support a generalized 'cardiovascular risk' statement without specifying the studied outcome population/claim framing.
Clinical trial benefits of Lipitor persist over 5+ years.
No duration of benefit beyond trial excerpts is provided in the supplied label excerpts.
Safety of Lipitor does not have an upper time limit when monitored.
No statement about an 'upper time limit' or duration of safety monitoring is present in the supplied excerpts.
There are no direct interactions between Lipitor and low-sodium diets.
No low-sodium diet interaction discussion is present in the supplied label excerpts.
Sodium restriction complements Lipitor by aiding blood pressure control.
No blood pressure or sodium restriction counseling is present in the supplied label excerpts.
Sodium restriction enhances statin efficacy without altering Lipitor drug metabolism or absorption.
No claim about sodium restriction affecting statin efficacy, metabolism, or absorption is present in the supplied label excerpts.
Lipitor is not affected by dietary sodium levels.
No statement about dietary sodium affecting atorvastatin pharmacokinetics or effect is present.
Muscle pain (myalgia) affects 5–10% of users of Lipitor.
Supplied label excerpt provides myalgia leading to discontinuation at 0.7% (Section 6.1), not a 5–10% user incidence range.
Rhabdomyolysis is a rare adverse effect of Lipitor occurring in <0.1% of users.
Supplied label excerpt notes rare cases of rhabdomyolysis (Section 5.1) but does not provide an incidence of <0.1%.
Liver enzyme elevations occur in 1–3% of users of Lipitor.
Supplied label excerpt provides persistent elevations >3x ULN occurred in 0.7% (Section 5.2) and transaminase increase leading to discontinuation at 0.4% (Section 6.1); it does not support 1–3%.
Liver enzyme elevations with Lipitor are usually mild and reversible.
The supplied excerpts do not explicitly characterize severity/reversibility.
Diabetes risk increases slightly in users of Lipitor (9% relative increase).
No diabetes risk or 9% relative increase is present in the supplied excerpts.
Cognitive effects like memory fog have been reported anecdotally for Lipitor but are not proven in large trials.
No cognitive/memory effects information is present in the supplied excerpts.
Baseline and periodic blood tests are recommended for long-term Lipitor use.
Label excerpt recommends liver function tests prior to and 12 weeks after initiation and after dose increase and periodically thereafter (Section 5.2), but does not support a generalized 'baseline and periodic blood tests' for long-term use across all contexts.
Liver function tests (ALT/AST) are recommended every 6–12 months initially, then annually for Lipitor.
Supplied label excerpt specifies prior to and at 12 weeks following initiation and/or dose increase and periodically (e.g., semiannually) thereafter; it does not specify 6–12 months initially or annual thereafter.
Creatine kinase (CK) should be checked for muscle symptoms in users of Lipitor.
The supplied excerpts mention CPK threshold definition for myopathy but do not state a monitoring recommendation to check CK for muscle symptoms.
HbA1c should be monitored for diabetes risk in users of Lipitor.
No HbA1c or diabetes-risk monitoring guidance is present in the supplied excerpts.
No special adjustments are needed for low-sodium diets when using Lipitor.
No low-sodium diet guidance or interaction content is present.
Electrolytes should be tracked if a patient is on diuretics alongside Lipitor.
No diuretic/electrolyte monitoring guidance is present in the supplied excerpts.
Heavy alcohol use is a reason to avoid or use caution with Lipitor.
No alcohol-specific precaution is present in the supplied excerpts.
Gemfibrozil is an interacting drug where caution/avoidance is recommended with Lipitor.
The supplied label excerpts mention 'fibric acid derivatives' with increased risk and general caution, but do not specifically mention gemfibrozil.
Low-sodium diets pose no added risks with Lipitor, even in kidney disease patients.
No sodium diet guidance and no statement linking sodium restriction to kidney disease risk is present. The only renal-related statement provided is that renal disease does not affect plasma concentrations/LDL-C reduction (Section 2 excerpt).
Using other statins such as rosuvastatin (Crestor) or pravastatin may have lower muscle risk profiles than Lipitor.
No comparative muscle-risk statements about other statins are present in the supplied excerpts.
Ezetimibe is a non-statin option for patients concerned about long-term statin use.
No non-statin alternatives (ezetimibe) are discussed in the supplied excerpts.
PCSK9 inhibitors (e.g., Repatha) are non-statin options for patients concerned about long-term statin use.
No PCSK9 inhibitor discussion is present in the supplied excerpts.
Bempedoic acid is a non-statin option for patients concerned about long-term statin use.
No bempedoic acid discussion is present in the supplied excerpts.
In high-risk cases, statins add 30–50% more benefit beyond low-sodium diet plus exercise for LDL reduction.
Supplied excerpts do not quantify additional benefit (30–50%) beyond low-sodium diet and exercise for LDL reduction.
Contradictions
Important Omissions
No mention of LIPITOR being an adjunct to diet and other nonpharmacologic measures, and no detail that lipid-altering agents should be only one component of multiple risk factor intervention (Section 1).
Importance:
Moderate
No mention that, for liver monitoring, LFTs are recommended prior to and at 12 weeks following initiation and/or dose increase, and periodically thereafter (e.g., semiannually) (Section 5.2).
Importance:
Moderate
No mention of contraindications/hypersensitivity to components (Section 4) beyond pregnancy and breastfeeding (some safety claims were made without covering hypersensitivity).
Importance:
Low
Safety Assessment
Potential Patient Risk:
Moderate
Multiple statements appear unsupported or numerically incorrect (e.g., specific adverse-event incidence rates, diabetes/cognitive claims, sodium-diet interaction statements, monitoring schedules). Unsupported guidance about monitoring/testing could mislead clinical decision-making if relied upon.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Numerous claims are not supported by the provided FDA label excerpts, including specific incidence percentages, monitoring schedules (ALT/AST, CK, HbA1c), dietary sodium interactions, diabetes/cognitive effects, and comparative/non-statin alternatives and quantified additive benefit.
Suggested Improvement
Restrict statements to those explicitly supported by the provided label excerpts (Sections 1, 2, 4, 5.1–5.2, 6.1, 7.1–7.3, 8.1, 8.3, 14). Remove unsupported quantitative and diet-related claims; replace monitoring/monitoring intervals with the label’s stated liver function test schedule (prior to and at 12 weeks after initiation and/or dose increase, periodically thereafter e.g., semiannually).